Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Clin Genitourin Cancer. 2017 Oct 16;16(2):e315–e322. doi: 10.1016/j.clgc.2017.10.001

Table 3.

Response Based on Disease Category

Response N %
Measurable disease (n=35)
Complete response 2 5.7
Partial response 9 25.7
Stable disease 10 28.6
Progression 9 25.7
Unevaluable 5 14.3
PSA (n=73)
Response 43 58.9
Stable disease 15 20.5
Progression 5 6.8
Unevaluable 10 13.7
Bone disease (n=63)
Response 2 3.2
Stable disease 38 60.3
Progression 10 15.9
Unevaluable 13 20.6